Curatis Holding AG
· ISIN: CH1330780979
· EQS - adhoc news
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Curatis Holding AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
23 May 2025 07:00AM
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Ad hoc announcement pursuant to Art. 53 LR
Liestal, Switzerland, 23 May 2025: An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema (PTBE) in association w...
Curatis Holding AG
27 March 2025 07:00AM
Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patientenzielgruppe beim Lead-Projekt C-PTBE-01
Ad hoc announcement pursuant to Art. 53 LR
Liestal, Schweiz, 27. März 2025: Die Curatis Holding AG (SIX:CURN, "Curatis") weist für das Jahr 2024 einen Geschäftserlös von CHF 6.9m aus, wobei die Curatis AG hierin nur für 8 Monate berücksichtigt ist. Die Curatis AG konnte den Umsatz im Vertriebsgeschäft im gesamten Jahr 2024 im Vergleich zu 2023 um 3...
Curatis Holding AG
11 March 2025 07:00AM
Curatis Announces Formation of Distinguished Advisory Board
Curatis Holding AG
/ Key word(s): Strategic Company Decision
Curatis Announces Formation of Distinguished Advisory Board
11.03.2025 / 07:00 CET/CEST
MEDIA RELEASE
Liestal, Switzerland, 11 March 2025: Curatis Holding (SIX:CURN) announces today the formation of an Advisory Board comprised of four internationally recognize...
Curatis Holding AG
14 November 2024 07:00AM
Curatis wird für C-PTBE-01 in den USA eine Biologic License beantragen - damit erhöht sich die Dauer des Marktschutzes in den USA markant im Falle einer Zulassung
Curatis Holding AG
/ Key word(s): Strategic Company Decision
Curatis wird für C-PTBE-01 in den USA eine Biologic License beantragen - damit erhöht sich die Dauer des Marktschutzes in den USA markant im Falle einer Zulassung
14.11.2024 / 07:00 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 14. November 2024: Curatis Holding (S...
Curatis Holding AG
16 September 2024 07:00AM
Deutlich gesteigerter Umsatz im Kerngeschäft und Projekte in Entwicklungs-Pipeline auf Kurs
Ad-hoc-Mitteilung gemäss Art. 53 KR
Liestal, Schweiz, 16. September 2024: Curatis Holding (SIX:CURN) weist für das H1 2024 einen Geschäfterlös von 2.0m CHF aus, wobei die Curatis AG hierin nur für 2 Monate berücksichtigt ist. Die Curatis AG konnte den Umsatz im Vertriebsgeschäft in den gesamten 6 Monaten 2024 im Vergleich zu den ersten 6 Monaten 20...
Curatis Holding AG
12 September 2024 07:46PM
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
Curatis Holding AG
/ Key word(s): Miscellaneous
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
12.09.2024 / 19:46 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 12. September 2024: Curatis Holding (SIX:CURN), ein Pharmaunternehmen mit Fokus auf Orphan Drugs und ...
Curatis Holding AG
12 September 2024 07:46PM
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
Curatis Holding AG
/ Key word(s): Miscellaneous
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
12.09.2024 / 19:46 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 12. September 2024: Curatis Holding (SIX:CURN), ein Pharmaunternehmen mit Fokus auf Orphan Drugs und ...
Curatis Holding AG
27 August 2024 05:45PM
Einreichung des Antrags für Orphan-Drug-Designation des wichtigsten Produktkandidaten in den USA
Curatis Holding AG
/ Key word(s): Expansion/Strategic Company Decision
Curatis auf Kurs: Einreichung des Antrags für Orphan-Drug-Designation des wichtigsten Produktkandidaten in den USA
27.08.2024 / 17:45 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 27. August 2024: Curatis Holding (SIX:CURN) hat bei der US-Medikamentenbehö...
Curatis Holding AG
25 July 2024 07:00AM
Initiation of Coverage and Publication of Equity Research Report by valuationLAB
Curatis Holding AG
/ Key word(s): Research Update
Curatis Holding AG: Initiation of Coverage and Publication of Equity Research Report by valuationLAB
25.07.2024 / 07:00 CET/CEST
MEDIA RELEASE
Curatis Holding (SIX:CURN) announces that the life science research company valuationLAB has initiated coverage and has issued a...
Curatis Holding AG
21 June 2024 05:13PM
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Curatis Holding AG
/ Key word(s): AGMEGM
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
21.06.2024 / 17:13 CET/CEST
MEDIA RELEASE
Liestal, Switzerland, 21 June 2024: Curatis Holding AG (CURN.SW), a SIX Swiss Exchange listed specialty pharmaceutical and therapeutic drug deve...
Curatis Holding AG
24 May 2024 07:00AM
Curatis Holding AG publishes Annual Report of the (then still named) Kinarus Group for FY2023 and announces appointment of Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR
Full Annual Report of Kinarus Therapeutics Holding AG for the financial year 2023 published today
Publication of audited consolidated & statutory FY2023 financial statements of Kinarus Therapeutics Holding AG already occurred on 17 April 2024
Patrick Ramsauer appointed as Chief Financial Officer of ...
Curatis Holding AG
More Curatis Holding AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN